Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NIAID

Insect Salivary Proteins, Particularly Sand Fly Salivary Proteins Work As Non-classical Natural Adjuvants Driving A Specific Immune Response That Accelerate The Immune Response To Another Protein Or Pathogen

  • Read more about Insect Salivary Proteins, Particularly Sand Fly Salivary Proteins Work As Non-classical Natural Adjuvants Driving A Specific Immune Response That Accelerate The Immune Response To Another Protein Or Pathogen
US Application 61/089,884
Filed on 2008-08-18

METHODS OF PREVENTING INFECTION BY HERPES VIRUSES OR TREATING REACTIVATION AFTER LATENCY IN A HOST BY INHIBITORS OF THE LSD1 PROTEIN

  • Read more about METHODS OF PREVENTING INFECTION BY HERPES VIRUSES OR TREATING REACTIVATION AFTER LATENCY IN A HOST BY INHIBITORS OF THE LSD1 PROTEIN
US Application 61/083,304
Filed on 2008-07-24

Device For Microwave-assisted Cryo-sample Processing

  • Read more about Device For Microwave-assisted Cryo-sample Processing
US Application 61/094,848
Filed on 2008-09-05

A High-Throughput Screen For T-Lymphocyte Antigens Using Proteins Expressed By In-Vitro Transcription By Translation And Coupled To Latex Heads

  • Read more about A High-Throughput Screen For T-Lymphocyte Antigens Using Proteins Expressed By In-Vitro Transcription By Translation And Coupled To Latex Heads
US Application 61/056,359
Filed on 2008-05-27

MONITORING TCR-B TO DETERMINE HIV THERAPY AND DISEASE PROGRESSION

  • Read more about MONITORING TCR-B TO DETERMINE HIV THERAPY AND DISEASE PROGRESSION
US Application 61/131,954
Filed on 2008-06-12

INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS

  • Read more about INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS
US Application 61/083,000
Filed on 2008-07-23

Sand Fly Salivary Proteins (LJM04, LJM11, LJM26, LJL143, And LJMI9) Which Have Anti-complement Activity And May Be Used To Treat Complement-related Diseases, And Also As Potential Leishimania Vaccine Candidates

  • Read more about Sand Fly Salivary Proteins (LJM04, LJM11, LJM26, LJL143, And LJMI9) Which Have Anti-complement Activity And May Be Used To Treat Complement-related Diseases, And Also As Potential Leishimania Vaccine Candidates
US Application 61/142,098
Filed on 2008-12-31

LJL143 Sand Fly Salivary Protein, A Novel Factor Xa Inhibitor

  • Read more about LJL143 Sand Fly Salivary Protein, A Novel Factor Xa Inhibitor
US Application 61/142,107
Filed on 2008-12-31

LJL143 AND LJM17 FROM LUTZOMIA LONGIPALPIS THAT ELICIT CELLULAR IMMUNITY TO LEISHMANIA INFATUM CHAGASI PARASITES

  • Read more about LJL143 AND LJM17 FROM LUTZOMIA LONGIPALPIS THAT ELICIT CELLULAR IMMUNITY TO LEISHMANIA INFATUM CHAGASI PARASITES
US Application 61/051,635
Filed on 2008-05-08

Molecular Scaffolds for HIV-1 Epitopes

  • Read more about Molecular Scaffolds for HIV-1 Epitopes
US Application 60/649,551
Filed on 2005-02-03

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 79
  • Page 80
  • Page 81
  • Page 82
  • Page 83
  • Page 84
  • Page 85
  • Page 86
  • Page 87
  • …
  • Next page ››
  • Last page Last »
Subscribe to NIAID
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health